GLP-1 Receptor Agonists and FGF21 Analogs May Be Key Treatments for MASH-Related Cirrhosis

Source: Pharmacy Times articles

New treatments for metabolic dysfunction-associated steatohepatitis (MASH)–related cirrhosis address unique challenges in drug development.
Read More